The latest announcement follows the recent US Food and Drug Administration (FDA) acceptance of the company’s new drug ...
Morgan Stanley expects the FDA to approve Gilead Sciences (NASDAQ:GILD)' Lenacapavir (LEN) for HIV prevention (PrEP) on or before its June 19 PDUFA date, a move that the bank believes could drive ...
A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
US antivirals giant Gilead Sciences recently announced that the US Food and Drug Administration (FDA) has accepted its New ...
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But without US foreign aid dollars, its delivery to millions worldwide is under ...
When Jeep owners complained ads were appearing while driving, the carmaker said it was a glitch. But as auto makers consider ...
Foster City, California Tuesday, February 25, 2025, 16:00 Hrs [IST] ...
6d
News Medical on MSNNew HIV therapy lenacapavir shows high efficacy in Ugandan populationA multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
Three bovine veterinarians had undetected H5N1 avian influenza infections despite no apparent contact with infected cows, suggesting that there may be U.S. states with unidentified positive cases of ...
Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...
A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results